Zacks Research Upgrades Lyell Immunopharma (NASDAQ:LYEL) to Hold

Lyell Immunopharma (NASDAQ:LYEL) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

LYEL has been the subject of a number of other reports. Robert W. Baird set a $49.00 target price on shares of Lyell Immunopharma and gave the company an “outperform” rating in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Needham & Company LLC reissued a “buy” rating and set a $44.00 target price on shares of Lyell Immunopharma in a research note on Thursday, May 7th. Finally, Citizens Jmp assumed coverage on shares of Lyell Immunopharma in a research note on Monday, March 9th. They set a “market outperform” rating and a $34.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Lyell Immunopharma Stock Down 2.3%

NASDAQ LYEL opened at $16.13 on Monday. The company has a fifty day moving average of $21.40 and a two-hundred day moving average of $23.58. The firm has a market capitalization of $376.31 million, a price-to-earnings ratio of -1.17 and a beta of -0.05. Lyell Immunopharma has a 52 week low of $7.65 and a 52 week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, hitting the consensus estimate of ($1.10). The company had revenue of $0.00 million during the quarter, compared to analyst estimates of $0.00 million. Lyell Immunopharma had a negative net margin of 794,858.12% and a negative return on equity of 85.71%. Equities research analysts anticipate that Lyell Immunopharma will post -8.37 EPS for the current year.

Institutional Trading of Lyell Immunopharma

Institutional investors and hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. raised its holdings in Lyell Immunopharma by 7.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 85,423 shares of the company’s stock worth $2,629,000 after purchasing an additional 5,913 shares in the last quarter. BBR Partners LLC acquired a new position in shares of Lyell Immunopharma during the fourth quarter valued at about $210,000. ExodusPoint Capital Management LP acquired a new position in shares of Lyell Immunopharma during the fourth quarter valued at about $262,000. Marshall Wace LLP acquired a new position in shares of Lyell Immunopharma during the second quarter valued at about $94,000. Finally, Two Sigma Investments LP increased its holdings in shares of Lyell Immunopharma by 107.0% during the third quarter. Two Sigma Investments LP now owns 20,827 shares of the company’s stock valued at $338,000 after acquiring an additional 10,768 shares in the last quarter. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.